Delivery Order SPE2DB24D1021-SPE2DB25FEZPU
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL, a pharmaceutical product used in the treatment of autoimmune conditions. The contract was awarded on September 25, 2025, with an ultimate completion date of September 26, 2025, and utilizes firm fixed price pricing with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the place of performance for this order....
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune and inflammatory conditions. This firm fixed price delivery order, awarded on August 29, 2025, with an ultimate completion date of September 2, 2025, represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order valued at $9,166.56 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price contract, awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, represents a non-competed delivery order under AmerisourceBergen's existing DLA contract vehicle. The place of performance is listed as the company's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $1,989.76 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used to treat inflammatory conditions. The award, issued on October 27, 2025, with an ultimate completion date of October 28, 2025, carries a firm fixed price and represents a non-competitive delivery order. Performance will occur at the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $19,051.96 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of inflammatory conditions. The award, issued on July 14, 2025, with an ultimate completion date of July 15, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. The contract is structured as a firm fixed price delivery order with an ultimate completion date of June 2, 2025. This award was not set-aside and represents a competitive procurement, indicating that AmerisourceBergen competed against other qualified vendors to secure this medical...
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price contract, awarded on July 17, 2025, with an ultimate completion date of July 18, 2025, was competitively awarded with no set-aside designation. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $2,265.90 delivery order to AmerisourceBergen Drug Corp for HUMIRA Pen 40 MG/0.8 MLS, a pharmaceutical product used in the treatment of autoimmune conditions. This contract, awarded on August 19, 2025, represents a firm fixed price delivery order with an ultimate completion date of August 20, 2025. The award was made through open competition with no set-aside designation, and the product will be delivered to AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product for immune-mediated conditions. Awarded on August 10, 2025, with an ultimate completion date of August 11, 2025, this firm fixed price delivery order represents a competitive award with no set-aside designation. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $2,039.08 to AmerisourceBergen Drug Corp for the supply of HUMIRA Pen 40 mg/0.8 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed price delivery order, issued on October 23, 2025, with an ultimate completion date of October 24, 2025, represents a competitive award with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FEZPUDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,812.52 to AmerisourceBergen Drug Corp for HUMIRA (Pen) 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed price delivery order, issued on August 12, 2025, with an ultimate completion date of August 13, 2025, represents a non-competitive, non-set-aside award executed under AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's substantial $999,999,999.00 IDC with DLA Troop Support Medical (contract number SPE2DX), which extends through December 2026 and serves as a global pharmaceutical support vehicle for military healthcare programs. As a major pharmaceutical distributor, AmerisourceBergen supplies a comprehensive range of medications and medical commodities to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The company has demonstrated substantial capability in federal medical procurement through competitive awards and holds significant market position within the DLA Medical Supply Chain, positioning it as a critical vendor for pharmaceutical support to military and veteran healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 8/12/25 |